The purpose of this study was to assess the effects of patiromer on serum potassium
participants with heart failure. This study also assessed the safety and tolerability of
patiromer in participants with heart failure.
The purpose of this study was to assess the effects of patiromer on serum potassium
participants with heart failure. This study also assessed the safety and tolerability of
patiromer in participants with heart failure.
Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease
Completed
Relypsa, Inc.
Phase 2
2010-05-01
The purpose of this study was to evaluate the feasibility of individualized titration of
patiromer according to serum potassium. This study also assessed the safety and tolerability
of patiromer and the effects of patiromer on serum potassium in heart failure (HF)
participants with chronic kidney disease (CKD).
Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
Completed
Relypsa, Inc.
Phase 2
2011-06-01
This study determined the optimal starting dose of patiromer in treating hyperkalemia in
participants with hypertension and diabetic nephropathy who were already receiving ACEI
and/or ARB drugs, with or without spironolactone. This study also evaluated the efficacy and
safety of patiromer and the long term use of patiromer.
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
Completed
Relypsa, Inc.
Phase 3
2013-02-01
The purpose of this study was to evaluate the efficacy and safety of patiromer
(investigational drug) in the treatment of hyperkalemia (high serum potassium). The study
also evaluated the effect of withdrawing patiromer treatment and assessed whether chronic
treatment with patiromer prevented the recurrence of hyperkalemia. The safety of patiromer
treatment was also evaluated.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
